Home › Compound Library › THC (Delta-9-Tetrahydrocannabinol)

THC (Delta-9-Tetrahydrocannabinol)

Cannabinoidoral · inferred

Primary psychoactive compound in cannabis. Highly lipophilic with extensive tissue distribution. Terminal half-life varies greatly: ~1.3 days in occasional users, up to 5-13 days in chronic users due to adipose redistribution. Metabolite THC-COOH detectable in urine for weeks.

Projected serum levels — 10 mg, as needed (shown daily)

THC (Delta-9-Tetrahydrocannabinol)
THC (Delta-9-Tetrahydrocannabinol) modeled serum levels, 10 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 3 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 3
THC (Delta-9-Tetrahydrocannabinol) modeled serum levels with a loading dose of 20.3 mg, then 10 mg as needed (shown daily) The first dose is larger so levels approach steady state faster. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg as needed (shown daily) (oral).

Loading schedule: 20.3 mg on day 1, then 10 mg as needed (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~3 days: peak ≈ 3.8 mg, trough ≈ 2.1 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Cannabinoid
Route modeled
Oral
Model confidence
inferred
Half-life
25 h
Common dose
10 mg
Reference dose range
1–50 mg (single dose)
Suggested cadence
as needed (shown daily)
Validated against
20 mg oral — Cmax 0.010 mg/L at 2 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + THC (Delta-9-Tetrahydrocannabinol) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change THC (Delta-9-Tetrahydrocannabinol) AUC by ~0.45x

  • danger
    Efavirenz (Sustiva) + THC (Delta-9-Tetrahydrocannabinol) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change THC (Delta-9-Tetrahydrocannabinol) AUC by ~0.32x

  • danger
    Levothyroxine (Synthroid) + THC (Delta-9-Tetrahydrocannabinol) Protein binding

    THC (Delta-9-Tetrahydrocannabinol) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index;…

  • danger
    Rifampin + THC (Delta-9-Tetrahydrocannabinol) CYP induction

    Rifampin inducer of CYP3A4 predicted to change THC (Delta-9-Tetrahydrocannabinol) AUC by ~0.32x

  • danger
    Tacrolimus (Prograf) + THC (Delta-9-Tetrahydrocannabinol) Protein binding

    THC (Delta-9-Tetrahydrocannabinol) may displace Tacrolimus (Prograf) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…

  • danger
    Warfarin (Coumadin) + THC (Delta-9-Tetrahydrocannabinol) Protein binding

    THC (Delta-9-Tetrahydrocannabinol) may displace Warfarin (Coumadin) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…

Serum checks 258 modeled interaction pairings for thc (delta-9-tetrahydrocannabinol) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Metabolism of Tetrahydrocannabinol in Frequent and Infrequent Marijuana Users Kelly P, Jones RT · Journal of Analytical Toxicology, 1992 DOI

    Compared THC and THC-COOH plasma and urine levels after 5 mg IV THC in frequent vs infrequent users, showing higher concentrations and longer detection in frequent users.

  2. Delta-9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC, and 11-Nor-9-carboxy-THC Plasma Pharmacokinetics during and after Continuous High-Dose Oral THC Karschner EL et al. · Clinical Chemistry, 2011 DOI

    Characterized plasma pharmacokinetics of THC and metabolites 11-OH-THC and THCCOOH during and after continuous high-dose oral THC administration, demonstrating prolonged detection windows.

  3. The Pharmacokinetics and the Pharmacodynamics of Cannabinoids Lucas CJ et al. · British Journal of Clinical Pharmacology, 2018 DOI

    Comprehensive review of cannabinoid pharmacokinetics including absorption, distribution, metabolism via CYP2C9/CYP3A4, and elimination with half-life estimates across different routes of administration.

3 published studies referenced in the app, each with a plain-language summary.